OBJECTIVE: To explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer. METHODS: Eligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N=107) completed standardized symptom measures: Brief Fatigue Inventory, Brief Pain Inventory, Menopause Specific Quality of Life Questionnaire, Functional Assessment of Cancer Therapy Neurotoxicity scales. Two performance measures assessed function: grip strength (Jamar dynamometer; n=71) and timed get-up-and-go (TUG; n=103). Analyses were performed with an overall symptom composite score. Correlations and multiple linear regression analyses were performed to test adverse effects on physical function. RESULTS: The mean age was 64 years (range 45–84), 81% white, 84% on an aromatase inhibitor, and on endocrine therapy for mean 35 months (range 1–130 months). Dominant hand grip strength was inversely correlated with symptom composite scores (r=−.29, p=.02). Slower TUG was positively correlated with higher Charlson comorbidity level (r=.36, p